Syd Labs研究级Atezolizumab生物类似药,内毒素0.05 EU/mg(Atezolizumab Biosimilar, Endotoxin 0.05 EU/mg)。研究级Atezolizumab生物类似蛋白仅供研究使用(RUO)。重组人IgG1同型对照(Recombinant human IgG1 isotype controls)是可用的。Atezolizumab结合并阻断小鼠PD-L1,而不是durvalumab。 Atezolizumab生物类似药 重点说明:...
Syd Labs研究级Atezolizumab生物类似药,抗人PD-L1单克隆抗体(Atezolizumab Biosimilar, Anti-human PD-L1 Monoclonal Antibody)。研究级Atezolizumab生物类似蛋白仅供研究使用(RUO)。重组人IgG1同型对照(Recombinant human IgG1 isotype controls)是可用的。Atezolizumab结合并阻断小鼠PD-L1,而不是durvalumab。 重点说明:此产...
Methods: This single-center retrospective study analyzed patients with ES-SCLC who received standard platinum–etoposide chemotherapy combined with atezolizumab or durvalumab immunotherapy as induction treatment, followed by consolidative thoracic radiotherapy (CTRT) before disease progression in the first-line ...
目前,已经上市的免疫检查点抑制剂 PD-1 或 PD-L1 抑制剂共 5 个,即 Tecentriq(Atezolizumab)、Imfinzi(Durvalumab)[2]、Bavencio(Avelumab)[3]、Opdivo(Nivolumab)[4]、Keytruda(Pembrolizumab)[5]。 近日, 瑞士医药巨头罗氏的新星药物 Tecentriq (Atezolizumab),接连获得美国 FDA 和欧洲 EMA 的批准,将广泛用于...
Systemic therapy for hepatocellular carcinoma has evolved from sorafenib to now include immune checkpoint blockade, either atezolizumab/bevacizumab or durvalumab/tremelimumab, and soon to include camrelizumab/rivoceranib and nivolumab/ipilimumab. Second-line therapy remains predominantly either a multikinase ...
For patients with head and neck squamous cell carcinoma and contraindications to cisplatin, durvalumab yielded worse PFS vs cetuximab. OncView™ Podcast: Advances in Systemic Therapy of Differentiated Thyroid Cancer Lori Wirth, MD May 12th 2022 Podcast In an OncView™ program, Lori Wirth, MD, ...
Durvalumab The risk or severity of adverse effects can be increased when Atezolizumab is combined with Durvalumab. Dyclonine The risk or severity of methemoglobinemia can be increased when Atezolizumab is combined with Dyclonine. Ebola Zaire vaccine (live, attenuated) The therapeutic efficacy of Ebola...
et al. An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer. Nat. Med. 27, 793–801 (2021). Article CAS PubMed Google Scholar Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for ...
免疫单药治疗——与Tecentriq类似,几款单药获益用于膀胱癌的免疫疗法,ORR较低,一线和二线均在30%以下。局部晚期或转移性膀胱癌不适合顺铂的一线治疗者,NCCN指南推荐帕博利珠单抗和阿塔珠单抗;局部晚期或转移性膀胱癌二线治疗NCCN指南推荐纳武利尤单抗、帕博利珠单抗、阿塔珠单抗、Avelumab和Durvalumab。
Durvalumab was investigated as a consolidative therapy in patients with stage III NSCLC, who had not progressed after two or more cycles of platinum-based chemotherapy. In this study, those randomized to durvalumab every 2 weeks vs placebo experienced a significant improvement in PFS 16.8 vs 5.6 ...